JPRN-jRCT1091220068Other不适用
Feasibility study of post-SBRT adjuvant chemotherapy with tegafur-uracil in patients with stage I non-small cell lung cancer - Feasibility study of post-SBRT UFT in stage I NSCLC
Kinji Nishiyama0 个研究点目标入组 30 人开始时间: 2011年7月31日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- Other
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. pathologically or cytologically proved non-small cell lung cancer
- •2. clinical stage I (T1>=2cm,T2=<4cm)
- •3. never received thoracic radiation therapy
- •4. PS 0-2
- •5. tumor size of >=2cm and =<4cm
- •6. Being pulmonary tumor
- •7. Older than 20 years old
- •8. principal organs have normal function
- •9. estimated survival more than 6 months
- •10. considered inoperable or refused operation
- •11. got informed consent
排除标准
- •1. pulmonary fibrosis found on chest radiography
- •2. syncronous or metachronous cancer with disease free interval within 5 years
- •3. had a history of chemotherapy for NSCLC within 5 years
- •4. indicated progressive disease before administration of UFT
- •5. under pregnancy
- •6. had angina, cardiac infarction or heart failure within 3 months with poor control
- •7. having poor control DM
- •8. having some infection
- •9. have fever higher than 38 degrees
- •10. routine use of steroids
研究者
相似试验
招募中
2 期
Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase ll randomised trial2024-511849-19-00Institut Jules Bordet147
进行中（未招募）
1 期
eo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trialuminal B Breast CancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004165-13-FRInstitut Jules Bordet190
撤回
2 期
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic CancerPancreatic AdenocarcinomaPancreatic CancerNCT04130399Indiana University
已完成
不适用
Feasibility study of adjuvant chemotherapy with S-1 in elderly patients with non-small-cell lung cancernon-small-cell lung cancerJPRN-UMIN000002383ung Oncology Group in Kyushu, Japan (LOGIK)25
已完成
2 期
Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for stage II-IIIA non-small cell lung cancerJPRN-UMIN000016191Division of Chest Surgery, Toho University Omori Medical Center42